Genmab Appoints CDO

Judith Klimovsky, MD, has been appointed executive vice president and chief development officer (CDO), Genmab. Dr. Klimovsky will lead the company’s global product development activities and will join the executive team.

Dr. Klimovsky will be responsible for Genmab’s product development strategy in line with the company’s corporate strategy. Dr. Klimovsky brings extensive drug development experience, most recently serving as senior vice president and global head, Oncology Clinical Development, at Novartis. She is a hematologist by training with experience in various roles at BMS, Merck and Novartis, as well as in hematology clinical practice.

"We are very pleased to welcome Judith to Genmab. She has a strong  track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future on the road to becoming a sustainably profitable biotech company," said Jan van de Winkel, Ph.D., chief executive officer of Genmab. "With Judith heading our product development efforts we will be able to bring forward truly differentiated products that have the potential to transform the treatment of cancer and provide great benefits to patients and their families in the future."

Dr. Klimovsky will be based at the company’s Princeton, NJ location, with regular travel to the company’s locations in Copenhagen, Denmark and Utrecht, The Netherlands.